Bronchial asthma is a cause of significant morbidity and mortality with increasing prevalence worldwide. Resveratrol, a natural polyphenol, exhibits a wide range of biological and pharmacological activities, such as anticarcinogenesis, cardiovascular protection, and anti-inflammatory effects. Thus it is of much interest to investigate possible immunomodulatory effects of resveratrol in bronchial asthma representing a new mechanism that has not yet been fully elucidated. Methods: This experiment was performed on 50 albino mice divided in 5 equal groups. The normal control group (group I) received a veheicle of saline. The Ova-untreated group (group II); received ovalbumin (OVA). The OVA- challenged group treated by Resveratrol (group III). The OVA- challenged group treated by Dexamethasone (group IV. OVA- challenged group treated by dexamethasone and resveratrol (group V). At the end of experiment in the 28th day (24 hours after the last challenge in the 27thday), serum was analyzed for total IgE (TIgE) levels and bronchoalveolar lavage (BAL) was investigated for inflammatory cell count. The lung tissues were examined for histopathology score and immunohistochemistry for TLR2, CD4 and CD8. Results: The untreated group of asthma model showed a significant increase in serum level of TIgE, the number of total inflammatory cells, inflammatory score and the number of positive TLR2, CD4+ and CD8+ when compared to normal group. The treatment by both of resveratrol and dexamethasone was better than treatment with resveratrol alone as it showed significant decrease in the whole studied parameters. Conclusion: We demonstrated the immunomodulatory effect of resveratrol preclinical in bronchial asthma induced model via suppression of TLR2, CD4 and CD8 expression. We could suggest using resveratrol as add- on therapy with dexamethasone to achieve more efficacies in management of bronchial asthma.